We are a team of innovators bringing high-impact products to life

Mr. Hochman has also served President of Accelerated Technologies, Inc., a medical device accelerator company now owned by Orchestra BioMed. Mr. Hochman has over 24 years of healthcare entrepreneurial, venture capital and investment banking experience. He is currently Chairman of the board for Motus GI, a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy. Mr. Hochman was a co-founder and until September 2020 served as a board member of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. Prior to joining Orchestra Medical Ventures, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc. during which time he led financing transactions for over twenty early-stage companies raising over $420 million. From 1999 to 2006, Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association for $750 million. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013 for over $600 million.

Since 2008, Mr. Sherman has also served as Chief Technical Officer of Accelerated Technologies, Inc. (ATI), a medical device accelerator company managed by Orchestra Medical Ventures. Funds managed by Orchestra Medical Ventures are shareholders in the Company. Mr. Sherman has over 25 years of management and entrepreneurial experience in the medical technology industry spanning interventional cardiology, cardiac electrophysiology, sudden cardiac death, stroke, surgery, GI, and neurovascular therapies. Mr. Sherman served as Chief Executive Officer and a Director of Caliber since 2009. He was a co-founder and served on the Board of BackBeat since 2010. He was a co-founder and served as Chief Executive Officer and a director of FreeHold since 2011. From 2009 until 2016, he served on the board of directors of Vivasure. He is a member of the board of directors of Motus GI. Prior to joining Orchestra Medical Ventures, from February 2002 until March 2008, Mr. Sherman held various positions in executive management for Cordis Neurovascular (CNV), a Johnson & Johnson company, including Executive Director R&D and Director of Strategic Marketing for stroke products. He had worldwide responsibility for all neurovascular R&D and global strategic marketing responsibilities for the stroke franchise, including budgets, portfolio of products and strategic planning. Mr. Sherman made significant contributions to the design and commercialization of a series of key products including the Enterprise Vascular Reconstruction Device and the Orbit Embolic Coil. From January 1997 until February 2002, Mr. Sherman played an integral role in the formation and development of Revivant Corp (acquired by Zoll) while working with Thomas J. Fogarty, M.D. at Fogarty Engineering. He was Revivant’s first employee and managed the design, development, and testing of the AutoPulse device from concept through market introduction. In addition to the R&D related activities, Mr. Sherman supported the clinical research, marketing, and intellectual property efforts. The AutoPulse is a lightweight, portable tool replacing the need for manual chest compressions during cardio-pulmonary resuscitation (CPR) for patients suffering from sudden cardiac arrest. From January 1995 until January 1997, Mr. Sherman held positions in research and development for Cardiac Pathways Corp., prior to its acquisition by Boston Scientific. Prior to Cardiac Pathways, he worked at Baxter Healthcare. In each of these companies, he participated in the creation, development and launch of products. Mr. Sherman has authored more than 85 U.S. patents with an additional 90+ published applications. He earned a BS degree in Bioengineering from the University of California, San Diego.

Dr. Rose is Executive Chairman of the Board of Directors of SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on serious unmet medical needs and biothreats. Previously, he had served as Chairman and CEO of SIGA. Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2012. From 1994 through 2007, he served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. In addition to his roles at SIGA, Dr. Rose holds a position as Executive Vice President – Life Sciences at MacAndrews & Forbes Incorporated, the holding company of Ronald O. Perelman and a related party to SIGA. In April 2013, he became a director for Mesoblast Inc. (NASDAQ: MESO), an advanced cellular medicine company, where he serves as chairman of the scientific and technology committee. In 2015, Dr. Rose became a director of Abiomed, Inc. (NASDAQ: ABMD), a leading provider of medical devices that provide circulatory support.

Since July 2018, he has served as the President and CEO of Procyrion, Inc., a development stage medical device company developing catheter-based circulatory support technologies for congestive heart failure patients. Previously, he was the Senior Vice President and Group President, Cardiovascular and Neuromodulation at Abbott following its acquisition of St. Jude Medical. Dr. Fain became Group President of St. Jude Medical in 2014 where he was responsible for global sales, marketing and clinical affairs across the entire St. Jude Medical portfolio worldwide. Dr. Fain joined St. Jude Medical in 1997 as Vice President, Systems Development as part of the company’s acquisition of Ventritex, Inc., where he had worked since 1987. He went on to become Senior Vice President, Clinical/Regulatory Affairs for the St. Jude Medical Cardiac Rhythm Management Division (CRMD) in 1998. He was later promoted to Executive Vice President, Development and Clinical/Regulatory Affairs for CRMD in 2005 and then President of CRMD in 2007. Prior to his role as Group President, Dr. Fain was President of the company’s Implantable Electronic Systems Division beginning in 2012 when its CRM and Neuromodulation Divisions merged. Dr. Fain received his M.D. from Stanford University School of Medicine and holds a Sc.B. degree in applied math/biology from Brown University.

Mr. Smith currently represents Ascent on the Board of Directors for Azevan Pharmaceuticals and BlinkBio, and is a Board Observer of Vivasure Medical. He is also the founder and Managing Partner of Digitalis Ventures, a venture capital firm that invests in fundamental new ideas in math and science to address complex health problems. He currently represents Digitalis as a Director of CareDox Inc. and as a Board Observer of Second Genome, Inc. Mr. Smith is a co-founder of Fuse Therapeutics. He is also a Visiting Scholar at Rockefeller University and an adjunct faculty member at the RU Center for Clinical and Translational Science. He is also a member of the Scientific Advisory Board for Brigham & Women’s Hospital in Boston. Previously, he was the founding Director of the Mount Sinai Institute of Technology and a Professor in the Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai. Mr. Smith received a B.A. (with honors) from Williams College and a J.D. from the University of Pennsylvania Law School.

Mr. Aryeh is the founder and managing general partner of JALAA Equities, LP, a private hedge fund focused on the biotechnology and specialty pharmaceutical sector and has served in such capacity since 1997. He has served as a member of the board of directors of Ligand Pharmaceuticals, Inc. (NASDAQ: LGND), a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. He has served as Ligand’s Chairman of its Nominating and Governance Committee since September 2006. He serves as the Chairman of the Board of Directors of Novelion Therapeutics and is also on the board of directors of the Cystic Fibrosis Foundation's Therapeutics Board.

Ms. Connealy is the chief financial officer of Immunovant, a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. At Immunovant, Ms. Connealy leads finance, investor relations, and human resources. She also serves as an advisor to Perfuse Therapeutics, an early-stage company focused on ophthalmic diseases. Prior to Immunovant, Ms. Connealy held a number of leadership roles including chief financial officer and chief operating officer of Kiva, a San Francisco-based nonprofit organization; global head of talent at the Bill & Melinda Gates Foundation, focused on talent management, compensation, benefits, and global mobility; and vice president of business operations at Salesforce.com. Ms. Connealy also had a long tenure as a corporate officer at Genentech, including CFO of research and development and other key global operational roles.

His focus is on cardiac catheterization and cardiac electrophysiology. His main areas of research are in clinical electrophysiology - mapping techniques in dilated cardiomyopathies, non-pharmacological therapy of arrhythmias - and non-pharmacological therapies for heart failure. Moreover, he serves as a Co-Director at the Center for Computational Medicine in Cardiology at Università della Svizzera Italiana in Lugano, Switzerland. He has been Professor of Cardiology at University Hospital in Magdeburg, Germany since 2008. He also serves as Scientific Director at the Fondazione Ticino Cuore. Dr. Auricchio is also a part-time professor in Cardiology at the University of L’Aquila (Italy). He was the President of the European Heart Rhythm Association (EHRA). Dr. Auricchio is the author of more than 250 peer reviewed articles, 6 books and more than 20 book chapters. Dr. Auricchio received his medical degree from medical school in Naples (Italy) and a Ph. D. in Cardiovascular Physiology from the University of Rome “Tor Vergata” (Italy). He completed his fellowship in Cardiology at Federico II - University of Naples, Italy.

Dr. Katzen is considered a pioneer of angioplasty thrombolysis and has a particular interest in treatment of aortic (AAA, TAA) and peripheral aneurysms, peripheral arterial disease (PAD) and critical limb ischemia, carotid artery disease, renal vascular hypertension, and vascular malformations. He has participated in the innovation of new therapies for a number of vascular diseases. He is a program director for the International Symposium on Endovascular Therapy (ISET) and Symposium on Clinical Interventional Oncology (CIO). Dr. Katzen received his medical degree from the University of Miami School of Medicine. He completed his radiology residency at the New York Hospital-Cornell Medical Center, with a fellowship in cardiovascular radiology at St. Vincent’s Hospital Medical Center in New York, as well as the University of Rome, Italy.

He is also the Founder of PVLoops, a cardiovascular educational software company. He is also creator of Harvi, an interactive simulation-based mobile application available for the iPad for teaching and researching the aspects of ventricular mechanics and hemodynamics. After earning a B.S. degree from Cornell University in Applied and Engineering Physics, Dr. Burkhoff obtained Ph.D. and medical degrees from The Johns Hopkins School of Medicine and completed a fellowship in Cardiology at The Johns Hopkins Hospital. In 1992, Dr. Burkhoff became an Associate Professor at the Columbia University School of Medicine and worked at Columbia University Medical Center where he ran the Cardiovascular Research Laboratory through 2003. Dr. Burkhoff then became the Director of the Jack Skirball Center for Cardiovascular Research of the Cardiovascular Research Foundation through 2005. In conjunction with and following this role, Dr. Burkhoff served as the Medical Director of several startup companies, including Impulse Dynamics, Inc. (2003-2014), a company focused on an implantable cardiac stimulator for the treatment of heart failure, Cheetah Medical, Inc. (2006-2012), an advanced hemodynamic monitoring technology company, as well as CircuLite (2009-2013), which he co-founded and which was acquired by HeartWare in 2013. He served as Vice President, Medical Science for Heartware until it was purchased in 2016 by Medtronic for $1.9 billion. Dr. Burkhoff’s expertise includes cardiovascular modeling and research in basic and clinical aspects of ventricular mechanics, cardiovascular monitoring, heart failure, device and pharmacologic treatments for heart failure, including left ventricular assist devices.

A graduate of Duke University School of Medicine, he completed his internship and residency at The John Hopkins University School of Medicine in Baltimore, Maryland. Following his residency, he completed his general and interventional cardiology fellowship at Duke University where he joined the faculty as the John B. Simpson Assistant Professor of Interventional Cardiology and Genomic Sciences. Dr Kandzari is the former Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, California. Before joining the Scripps faculty, he also served as Chief Medical Officer for the Cordis Corporation, a Johnson & Johnson Company. He has also served as a Medical Officer for the Center for Devices and Radiological Health for the United States Food and Drug. Board certified by the American Board of Internal Medicine and its subspecialty Board of Cardiovascular Disease and Board of Interventional Cardiology, Dr Kandzari has held national and international leadership roles in clinical trials in cardiovascular disease and has participated in national and international program committees in cardiology. He has authored and coauthored more than 200 studies, book chapters and scientific reviews.

Dr. Kereiakes has been an original investigator for most of the interventional technologies introduced in the last two decades and has performed more than 30,000 catheterization procedures. In addition to lecturing nationally and internationally, Dr. Kereiakes is very active as a clinical and scientific investigator and has participated in over 1,300 clinical research protocols. He has published over 800 journal articles, abstracts and book chapters. He has served on the numerous editorial boards of prestigious, peer-reviewed journals, including Circulation, The Journal of the American College of Cardiology (JACC). Dr. Kereiakes received his medical degree and was valedictorian of his graduating class at the University of Cincinnati in Ohio. His postgraduate training included internship and residency at the University of California, San Francisco, a senior residency at Massachusetts General Hospital in Boston, and a chief residency at the University of California, San Francisco. He then completed fellowships in adult cardiology at the University of California, San Francisco and in coronary angioplasty at the San Francisco Heart Institute and the Sequoia Hospital.

Dr. Stone is an expert in cardiovascular research. His expertise includes; design and conductance of clinical trials specifically trials related to treatment of hypertension. Dr. Stone participates in the scientific advisory board of numerous cardiovascular trials including leading device trials for the treatment of hypertension. Dr. Stone is the founder of TCTMD.com, Associate Editor, JACC Cardiovascular Imaging and on the editorial board of many cardiovascular journals. Dr. Stone served in the medical and scientific advisory board of more than 100 clinical studies. Dr. Stone is the author of hundreds of Journal articles and the author of 34 books and book chapters. Dr. Stone received his medical degree from The Johns Hopkins School of Medicine Baltimore, MD. He completed his internship and residency, at the New York Hospital-Cornell Medical Center, New York City, NY; fellowship in Cardiology at Cedars-Sinai Medical Center, Los Angeles, CA and fellowship in Advanced Coronary Angioplasty at Mid America Heart Institute St. Luke's Hospital Kansas City, MO.

Dr. Scott offers his patients a breadth of experience and expertise in bariatric surgery, having worked in the field for more than 20 years. During that time, he has seen complications decrease ten-fold, and has played an important role in that improvement through his involvement in training, education, new techniques and technologies. Most recently, Dr. Scott served as an associate professor in general surgery for the University of Missouri at Columbia, and co-director of Missouri Bariatric Services. He has also served on the clinical faculty of schools including St. Louis University and the University of Health Sciences College of Osteopathic Medicine, and on the faculty of the Advanced Laparoscopic Training Center in Atlanta. Dr. Scott is an active researcher, presenter and author, and possesses a level of knowledge in his field that ensures patients receive the latest, most advanced bariatric care. He recently authored 3 text book chapters on the topic. In addition to his medical training, Dr. Scott is the co-founder and co-director of Towertech Research Group, a medical technique/procedure research entity. He has served on the boards of numerous entities including the American Hernia Society, the Ethicon Endo-Surgery Institute and on advisory boards for General Surgery Innovations and U.S. Surgical Corp. Dr. Scott has been the director of the Robotic Program at American Society of Metabolic and Bariatric Surgeons, moderator of the robotic session at Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) forums, spoken extensively on revisional bariatric surgery at SAGES, the American Society of Metabolic and Bariatric Surgery (ASMBS), the American College of Surgeons (ACS) and surgical disruptive technologies conferences. He holds memberships in the International Federation for the Surgery of Obesity and Metabolic Disorders, the International College of Surgeons, ASMBS, the American Hernia Society, the American Society of General Surgeons, the ACS, and SAGES.

Dr. Singh is the Deputy editor of the Journal of American College of Cardiology: Clinical EP, the editor in chief of Current Treatment Options in Cardiovascular Medicine, was the international associate editor of European Heart Journal and is in the editorial board of: EP Lab Digest and Journal of Innovation in Cardiac Rhythm Management. Dr. Singh serves on the steering committee and scientific advisory board of numerous national and international clinical trials mainly Dr. Singh is the author of more than 250 Journal articles and the author of 4 books and book chapters. Dr. Singh received his medical degree from B.J. Medical College, Pune University, India. He completed his Ph.D. studies at Oxford University, his residency and fellowship at Massachusetts General Hospital.

Prior to joining SIU, Dr. Flack held numerous positions at Wayne State University School of Medicine in Detroit, most recently as professor of medicine and physiology. He was chair of Wayne State’s internal medicine department for 8 years. While at Wayne State, Flack served as the founding director of the Division of Translational Research and Clinical Epidemiology (TRaCE) and was principal investigator of the National Institute of Environmental Health Sciences (NIEHS)-funded Center for Urban Health. Dr. Flack serves as the Vice President of the ASH Hypertension Specialist Board. Dr. Flack is the prior President of International Society on Hypertension in Blacks (ISHIB) and is also past member, FDA Cardio-renal Advisory Panel. Dr. Flack is the author of more than 180 publications and 18 books and book chapters. Dr. Flack is an Associate Editor of American Journal of Hypertension and CardioRenal Medicine. Dr. Flack received his medical degree from the University of Oklahoma Health Sciences Center. He completed his internship and residency at the University of Oklahoma Health Sciences Center and NIH post-doctoral fellowship in cardiovascular epidemiology at University of Minnesota.

He is also an Assistant Professor of Medicine at Columbia University College of Physicians and Surgeons and a Co-Director of TCT. Dr. Granada is one of the world’s foremost investigators in the field of translational research involving advanced experimental methodologies, endovascular imaging and emerging cardiovascular therapies. He has helped to develop and successfully validate several endovascular imaging and cardiovascular device technologies currently in clinical use worldwide. In addition, he is an active participant in the development of multiple innovation programs around the world. Dr. Granada received his medical degree from the Institute of Health Sciences in Medellin, Colombia. He completed his cardiovascular disease and interventional cardiology fellowships at Baylor College of Medicine in Houston, Texas. He joined CRF in 2007 from the Methodist Hospital Research Institute in Houston, Texas.

Dr. Kuck has served as a Board Member of the European Heart Rhythm Association (EHRA) for the past 4 years and serves as EHRA President. Dr. Kuck was the president German Cardiac Society (GCS) and a board member of the European society of cardiology (ESC). Dr. Kuck is the author of more than 400 publications, many books and book chapters and scientific reviews. Dr. Kuck serves on the editorial boards of the German Journal of cardiology, the Chinese Journal of Cardiology and the Journal of Cardiovascular Electrophysiology. Dr. Kuck received his medical degree from the University of Cologne, Germany. He completed his internship in Department of Cardiology of the University Hospital Eppendorf (UHE) Hamburg, Germany and his fellowship at the department of Clinical Electrophysiology of the University Hospital Limburg in Maastricht, Netherlands.

Through this program he is leading the way in training a new generation of interventional cardiologists. With a primary focus on complex coronary interventions and new technology development, Dr. Teirstein has played an active role in the initial development and clinical investigation of coronary stent procedures, rotablator atherectomy, transluminal extraction atherectomy, coronary angioscopy and the utilization of cardiopulmonary support. Dr. Teirstein pioneered the first effective treatment for restenosis (low dose radiation therapy) and was one of the early investigators of medicated stents. Recent areas of investigation include new technology for minimally invasive transcatheter aortic valve replacement (PARTNER trial) and transcatheter treatment of hypertension (Simplicity trial). The author of numerous publications, Dr. Teirstein has lectured throughout the world on state-of-the-art interventional cardiology techniques. He is an internationally recognized leader in cardiology and has received numerous awards for both research and clinical excellence. Dr. Teirstein completed medical school at Mount Sinai School of Medicine followed by internship and residency at Brigham and Women’s Hospital. He completed his fellowships St Luke’s Mid America Heart Institute and Stanford University Hospital.

He has served as director of the Cat labs from 2014-2017. In 2017, Dr. Stella was appointed Research Manager for the Division of Heart & Lungs of the University Medical Center Utrecht. Dr. Stella has been involved in many trials as principal investigator and has authored more than 140 peer-reviewed publications. He has also been invited to be a guest-faculty at major conferences such as Euro-PCR, TCT, Asia-live, ICI, CIT, CRF, India live and has also conducted local proctoring in Europe, Asia/China and the US. Dr. Stella’s current interests include reduction of DAPT with new stents, new stent designs and Transcatheter Valve techniques. He is a visiting professor of Medicine at the National University of Singapore and University of Sozhou in China.

He was previously Director of the Center for Applied Vascular Biology and Interventions, Mayo Foundation. Dr. Schwartz has also served as Professor at the Mayo Medical School. He holds Board Certifications on the National Board of Medical Examiners in Internal Medicine, the American Board of Internal Medicine in Cardiovascular Diseases, and the Society of Cardiovascular Computed Tomography (SCCT). Dr. Schwartz has published over 500 articles and abstracts in peer reviewed journals dealing with various topics in Interventional Cardiology and Advanced Cardiac Imaging. He is the recipient of various awards including the Andreas Gruentzig Award for Basic Research in Coronary Restenosis from the Thoraxcenter/European Society of Cardiology. He holds professional memberships as Fellow of the American College of Cardiology, American Heart Association, and The Society for Cardiac Angiography and Interventions. Dr. Schwartz is also a member of the Society of Atherosclerosis Imaging. Dr. Schwartz received a Bachelor’s degree in Engineering Physics, a Master’s degree in Electrical Engineering, and his doctorate from the University of Colorado-Denver and continued his internship, residency, and Fellowship at the Mayo Graduate School of Medicine.

Most recently, Dr. de la Torre served as an associate professor and director of the Bariatric Program at the University of Missouri at Columbia, and as director of the school's BioDesign and Innovation Program. He has also served on the faculty of schools including University of Health Sciences College of Osteopathic Medicine and St. Louis University, and on the faculty of the Advanced Laparoscopic Training Center in Atlanta. Dr. de la Torre offers his patients a wealth of experience and expertise in bariatric surgery, having worked in the field for more than 15 years. He has been the recipient of numerous awards, most notably a U.S. News and World Report High Performing Specialty Award, along with others recognizing his surgical and overall care skills. Dr. de la Torre has been an active researcher and author, writing multiple papers, abstracts and articles detailing advances and methods in bariatric and laparoscopic surgical techniques. His level of knowledge in this area ensures patients receive the latest most advanced care in bariatric and minimally invasive procedures. In addition to his medical training, Dr. de la Torre holds over 65 patents, and was recently inducted into the National Academy of Inventors. He is the co-founder and director of Towertech Research Group, a medical technique/procedure research entity. He is listed among Who’s Who of Science and Engineering and Who’s Who of American Inventors. Dr. de la Torre's professional memberships include the American College of Surgeons, the International College of Surgeons, the Society of Laparoendoscopic Surgeons, the Society of American Gastrointestinal Endoscopic Surgeons, the American Society for Metabolic & Bariatric Surgery, and the American Society of General Surgeons. In 2021, Dr. de la Torre was named the unanimous winner of the ASMBS Foundation's Surgical Innovation Award.

He is a member of the European Association of Percutaneous Cardiovascular Interventions and a member of the Belgian Working Group on Interventional Cardiology, and has been appointed as Visiting Professor at the University of Brussels. Dr. Verheye is the author of over 150 peer-reviewed journals (www.pubmed.com), ten book chapters, over 300 abstracts, and has led (as global principal investigator) and participated in numerous clinical (Phase I and II) and pre-clinical research studies in the field of innovative interventional cardiology (coronary and structural heart disease). He has presented at numerous major conferences such as TCT (Transcatheter Cardiovascular Therapeutics), EuroPCR (European Percutaneous Course on Revascularization), AsiaPCR, AHA (Amercian Heart Association), ACC (American College of Cardiology) and ESC (European Society of Cardiology) and has directed and transmitted several coronary and structural live cases to TCT, EuroPCR and ESC. His entrepreneurial interests led to the co-foundation of Hilbert Paradox, NV, a start-up company encompassing a unique way of capturing and correlating digital health data, applying data- and knowledge engineering, which was later on acquired by a clinical research organization. Afterwards he co-founded ainthoven, NV, a start-up company dedicated to on-line cardiac signal analytics by exploring the hyperspace of learning algorithms.

Dr. Reddy’s pioneering clinical research is changing the way cardiac patients are treated and cured. Under his leadership, Mount Sinai is the lead investigator on several multinational clinical trials exploring new arrhythmia procedures and technologies. Dr. Reddy is the author of more than 200 Journal articles and the author of 6 books and book chapters. Dr. Reddy received his medical degree from the Univ. of Michigan Medical School. He completed his residency in Internal Medicine at Yale-New Haven Hospital, his fellowship in Cardiovascular Discipline at University of Chicago Hospitals and his fellowship in electrophysiology at Massachusetts General Hospital.